Tenet Healthcare (THC) traded lower Monday, April 13, 2026, with the drop aligning with a fresh negative catalyst on the name: a Baird analyst downgrade to Neutral from Outperform alongside a reduced price target to $137 from $153. With the stock still priced for strong execution after a large multi-year run, the downgrade acted as an immediate trigger for profit-taking and de-risking.

The downgrade lands as investors continue to weigh Tenet’s operating momentum against policy-sensitive earnings risk in 2026. Tenet has guided for a headwind tied to the expected expiration of enhanced ACA premium tax credits, assuming a 20% reduction in ACA exchange enrollment and estimating about a $250 million impact to 2026 adjusted EBITDA, primarily in the hospital segment. That risk has become a recurring overhang as the market tries to handicap volume, payer mix, and bad-debt trends if exchange coverage rolls off more than expected.

Near-term trading is likely to be driven by (1) additional rating/target changes, (2) any datapoints on 2026 exchange enrollment and effectuation rates, and (3) Tenet’s next earnings report, where investors will look for updates on payer mix, same-facility volumes, and whether mitigation actions (including revenue-cycle support capabilities) are offsetting the exchange-related drag. If management reiterates or worsens the estimated exchange impact, the stock could remain under pressure even without a broader sector selloff.